These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 11118472)

  • 1. Clarification of anastrozole/megestrol acetate trial program design.
    Howell A
    J Clin Oncol; 2000 Dec; 18(24):4109. PubMed ID: 11118472
    [No Abstract]   [Full Text] [Related]  

  • 2. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group.
    Buzdar AU; Jones SE; Vogel CL; Wolter J; Plourde P; Webster A
    Cancer; 1997 Feb; 79(4):730-9. PubMed ID: 9024711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hormonal therapy in early and advanced breast cancer.
    Buzdar AU
    Breast J; 2004; 10 Suppl 1():S19-21. PubMed ID: 14984485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical overview of anastrozole--a new selective oral aromatase inhibitor.
    Jonat W
    Oncology; 1997; 54 Suppl 2():15-8. PubMed ID: 9394855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group.
    Buzdar AU; Jonat W; Howell A; Jones SE; Blomqvist CP; Vogel CL; Eiermann W; Wolter JM; Steinberg M; Webster A; Lee D
    Cancer; 1998 Sep; 83(6):1142-52. PubMed ID: 9740079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Future directions in endocrine treatment of advanced breast cancer.
    Bland KI
    Ann Surg Oncol; 1999 Dec; 6(8 Suppl):14S-16S. PubMed ID: 10619455
    [No Abstract]   [Full Text] [Related]  

  • 7. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.
    Buzdar A; Jonat W; Howell A; Jones SE; Blomqvist C; Vogel CL; Eiermann W; Wolter JM; Azab M; Webster A; Plourde PV
    J Clin Oncol; 1996 Jul; 14(7):2000-11. PubMed ID: 8683230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [ECCO 9 -- Future trends in endocrine therapy of breast cancer].
    Tumori; 1997; 83(5):874-6. PubMed ID: 9446251
    [No Abstract]   [Full Text] [Related]  

  • 9. Emerging role of aromatase inhibitors in the treatment of breast cancer.
    Harvey HA
    Oncology (Williston Park); 1998 Mar; 12(3 Suppl 5):32-5. PubMed ID: 9556789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate.
    Buzdar A; Douma J; Davidson N; Elledge R; Morgan M; Smith R; Porter L; Nabholtz J; Xiang X; Brady C
    J Clin Oncol; 2001 Jul; 19(14):3357-66. PubMed ID: 11454883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Promising results for Arimidex and Femara.
    Expert Rev Anticancer Ther; 2001 Dec; 1(4):508-9. PubMed ID: 12113080
    [No Abstract]   [Full Text] [Related]  

  • 12. [Aromatase inhibitors: anastrozole versus tamoxifen as first-ine therapy for advanced postmenopausal breast cancer].
    Bergmann L
    Strahlenther Onkol; 2001 May; 177(5):273-4. PubMed ID: 11398617
    [No Abstract]   [Full Text] [Related]  

  • 13. Anastrozole. A review of its use in the management of postmenopausal women with advanced breast cancer.
    Wiseman LR; Adkins JC
    Drugs Aging; 1998 Oct; 13(4):321-32. PubMed ID: 9805213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Focus on anastrozole and breast cancer.
    Mokbel K
    Curr Med Res Opin; 2003; 19(8):683-8. PubMed ID: 14687437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Letrozole in breast cancer.
    Shahab N
    N Engl J Med; 2004 Feb; 350(7):727-30; author reply 727-30. PubMed ID: 14971058
    [No Abstract]   [Full Text] [Related]  

  • 16. Network Meta-Analysis Comparing Overall Survival for Fulvestrant 500 mg Versus Alternative Therapies for Treatment of Postmenopausal, Estrogen Receptor-Positive Advanced Breast Cancer Following Failure on Prior Endocrine Therapy.
    Telford C; Jones N; Livings C; Batson S
    Clin Breast Cancer; 2016 Jun; 16(3):188-95. PubMed ID: 26971303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aromatase inhibitors come of age.
    Dowsett M
    Ann Oncol; 1997 Jul; 8(7):631-2. PubMed ID: 9296213
    [No Abstract]   [Full Text] [Related]  

  • 18. [Aromatase inhibitors: a review of clinical trials].
    Kerbrat P; Lefeuvre C
    Bull Cancer; 2000 Dec; 87 Spec No():31-39. PubMed ID: 11250606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer: methodologic issues.
    Winquist E; Bramwell V; Vandenberg T
    J Clin Oncol; 2002 Sep; 20(17):3748-9; author reply 3749-50. PubMed ID: 12202679
    [No Abstract]   [Full Text] [Related]  

  • 20. Pivotal trials of letrozole: a new aromatase inhibitor.
    Smith IE
    Oncology (Williston Park); 1998 Mar; 12(3 Suppl 5):41-4. PubMed ID: 9556791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.